martes, 22 de enero de 2013

Ernst & Young: Emergerán mergers (M&A)... / Closing the gap?

Even as its revenues have diminished in recent years, big pharma has managed to deliver robust shareholder returns through measures such as increased dividends and share repurchases. But such measures cannot be sustained without strong cash flows. 
With sales declining for the first time in 2012, it is only a matter of time before shareholder returns follow suit — unless pharma can fi nd new sources of growth. 

 With few options for organic growth, pharma needs transactions — for which it needs firepower*. More than ever, measures to boost and conserve firepower are vital. (Ver)

·   (*) “firepower”  a company’s capacity for conducting M&A deals

Corrigiendo el GAP...

Get ready for the return of the $10 billion-plus drug deal.

Pharmaceutical companies including Pfizer Inc. and Bristol- Myers Squibb Co. have spent the last several years digesting earlier acquisitions, refocusing their product development and setting aside cash in anticipation of expiring patents. Now, the expectation is they’re ready to start buying again. Led by Pfizer, in New York, and Whitehouse Station, New Jersey-based Merck &Co., five of the largest U.S. drugmakers had more than $70 billion in cash, near cash and short-term investments at the end of the third quarter. (Más

SAN FRANCISCO, Jan. 7, 2013 /PRNewswire/
Big pharma companies are facing a widening "growth gap" that will increase pressure to drive growth through mergers and acquisitions (M&A). But big pharma's attempts to make deals will be challenged by its diminished resources and fiercer competition for attractive assets from rapidly growing big biotech and specialty pharma companies. These and other findings were released today by Ernst &Young in the report Closing the gap? Big pharma's growth challenge and implications for deals. (Más)

Por ejemplo...

Merck &Co. Chief Executive Officer Kenneth Frazier said the drugmaker may be interested in buying Bausch & Lomb, the eye-care company for sale by Warburg Pincus LLC for at least $10 billion. “It’s something that’s worth thinking about, that’s the most I can say,” Frazier said in an interview yesterday at the JPMorgan Chase & Co. health conference in San Francisco. (Más)

Ver también:
Joe sólo tiene 4 $ billion para la compra

No hay comentarios: